Cover Image
市場調查報告書

家族性高膽固醇血症(II型量脂蛋白血症):開發平台分析

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 192585
出版日期 內容資訊 英文 104 Pages
訂單完成後即時交付
價格
Back to Top
家族性高膽固醇血症(II型量脂蛋白血症):開發平台分析 Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2015
出版日期: 2015年10月30日 內容資訊: 英文 104 Pages
簡介

家族性高膽固醇血症是先天罕見型絕症的一種。特徵是血液中存在高濃度的低比重脂蛋白(LDL)。由於LDL受體不足造成血液中LDL水準上升,於是便提升了膽固醇濃度。脂蛋白的作用是搬運血中的膽固醇,但血中濃度一高便表示膽固醇濃度也高。主要的症狀有膽固醇·LDL的濃度上升,及眼皮周圍出現黃色斑點、角膜末端變白(角膜圈)、手·腳肌腱出現腫塊(皮膚黃色瘤)、跟肌腱肥厚(皮膚下腫塊)等。

本報告提供全球各國治療家族性高膽固醇血症(II型血脂異常症)所用之開發中產品的開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

家族性高膽固醇血症(II型量脂蛋白血症)概要

治療藥的開發

  • 家族性高膽固醇血症開發中產品:概要
  • 家族性高膽固醇血症開發中產品:比較分析

各企業開發中的家族性高膽固醇血症治療藥

大學/研究機關研究中的家族性高膽固醇血症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

家族性高膽固醇血症治療藥:開發中的產品一覽(各企業)

家族性高膽固醇血症治療藥:研究中的產品一覽(大學/研究機關別)

家族性高膽固醇血症開發治療藥的企業

  • Aegerion Pharmaceuticals, Inc.
  • Cerenis Therapeutics Holding SA
  • CymaBay Therapeutics, Inc.
  • Gemphire Therapeutics Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • RegenxBio Inc.
  • Sanofi
  • Thetis Pharmaceuticals LLC

家族性高膽固醇血症:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型
  • 各治療分類

藥物簡介

  • (ezetimibe + atorvastatin calcium)
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • AEM-28
  • AEM-28-02
  • AEM-2814
  • alirocumab
  • AM-0010
  • anacetrapib
  • Antisense Oligonucleotides to Inhibit ApoB100 for Familial Hypercholesterolemia
  • bococizumab
  • BSN-272
  • CER-001
  • evinacumab
  • gemcabene calcium
  • lomitapide mesylate
  • MBX-8025
  • mipomersen sodium
  • RGX-501
  • TP-452

家族性高膽固醇血症治療藥:開發中產品的最新趨勢

家族性高膽固醇血症治療藥:開發暫停的產品

家族性高膽固醇血症治療藥:開發中止的產品

家族性高膽固醇血症相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7251IDB

Summary

Global Markets Direct's, 'Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2015', provides an overview of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Overview
  • Therapeutics Development
    • Pipeline Products for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Overview
    • Pipeline Products for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Comparative Analysis
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Therapeutics under Development by Companies
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Therapeutics under Investigation by Universities/Institutes
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Products under Development by Companies
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Products under Investigation by Universities/Institutes
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Companies Involved in Therapeutics Development
    • Aegerion Pharmaceuticals, Inc.
    • Cerenis Therapeutics Holding SA
    • CymaBay Therapeutics, Inc.
    • Gemphire Therapeutics Inc.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • RegenxBio Inc.
    • Sanofi
    • Thetis Pharmaceuticals LLC
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (ezetimibe + atorvastatin calcium) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AEM-28 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AEM-28-02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AEM-2814 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • alirocumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AM-0010 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • anacetrapib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotides to Inhibit ApoB100 for Familial Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bococizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BSN-272 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CER-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • evinacumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • gemcabene calcium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lomitapide mesylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-8025 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mipomersen sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RGX-501 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-452 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Recent Pipeline Updates
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Dormant Projects
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Discontinued Products
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 01, 2015: Sanofi And Regeneron Announce New Positive Praluent Phase 3 Data Presented At Esc Congress 2015
      • Aug 03, 2015: Isis Reports Positive Data from KYNAMRO (mipomersen sodium) FOCUS FH Phase 3 Study in Patients with Severe Heterozygous Familial Hypercholesterolemia
      • Jul 24, 2015: Sanofi And Regeneron Announce FDA Approval Of Praluent (Alirocumab) Injection, The First Pcsk9 Inhibitor In The U.S., For The Treatment Of High LDL Cholesterol In Adult Patients
      • May 26, 2015: Aegerion Pharmaceuticals Achieves Primary Endpoint in Phase III Study of Lomitapide in Japanese Patients With Homozygous Familial Hypercholesterolemia (HoFH)
      • Apr 30, 2015: AOP Orphan Launches Lojuxta (lomitapide) for Treatment of Homozygous Familial Hypercholesterolaemia to the Austrian Market
      • Apr 23, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia
      • Mar 25, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Homozygous Familial Hypercholesterolemia
      • Jan 28, 2015: Aegerion Investigated by Former Louisiana Attorney General and Special Prosecutor Richard P. Ieyoub and the Firm of Ieyoub O'Bell & Myers
      • Nov 18, 2014: Genzyme And Isis Present KYNAMRO Clinical Data At The American Heart Association
      • Sep 02, 2014: Isis Pharmaceuticals Presents Data On KYNAMRO At European Society of Cardiology Congress 2014
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), H2 2015
  • Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd...1)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Aegerion Pharmaceuticals, Inc., H2 2015
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Cerenis Therapeutics Holding SA, H2 2015
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by CymaBay Therapeutics, Inc., H2 2015
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Gemphire Therapeutics Inc., H2 2015
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Merck & Co., Inc., H2 2015
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Pfizer Inc., H2 2015
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by RegenxBio Inc., H2 2015
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Sanofi, H2 2015
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline by Thetis Pharmaceuticals LLC, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics - Recent Pipeline Updates, H2 2015
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Dormant Projects, H2 2015
  • Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), H2 2015
  • Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top